Current Report Filing (8-k)
July 18 2014 - 12:52PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549 FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
July 18, 2014
Date of Report (Date of Earliest Event
Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
000-31187 |
870638336 |
(State or other jurisdiction of |
(Commission File |
(IRS Employer Identification |
incorporation) |
Number) |
No.) |
6425 Abrams, Ville St- Laurent, Quebec, Canada
|
H4S 1X9 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code: (514)
331-7440
Check the appropriate box below if the Form 8K fining is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17CFR230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17CFR 240.14a -12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
[ ] Pre-commencement communication pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01 Other Events - News Release
IntelGenx to Host Management Call
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
INTELGENX TECHNOLOGIES CORP.
Dated: July 18, 2014 |
By: |
/s/ Paul A.
Simmons
|
|
|
Paul A. Simmons |
|
|
Chief Financial Officer
|
Exhibit 99.1
IntelGenx to Host Management Call
SAINT LAURENT, QUEBEC, July 15, 2014 - IntelGenx
Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (IntelGenx) today announced that its interim CEO, Dr. Horst G. Zerbe, will be
hosting a conference call on July 23rd, 2014 at 10:00 AM Eastern Time.
During the conference call, Dr. Zerbe will
provide a business update and discussion regarding the Companys recent
management changes. After managements comments, the call will be opened for
questions.
An accompanying webcast will also be
provided. Please refer to the information below for conference call dial-in
information and webcast registration.
Conference
dial-in: |
|
877-269-7756 |
International
dial-in: |
|
201-689-7817 |
Conference Call
Name: |
|
IntelGenx Management Update
Call |
Webcast
Registration: |
|
CLICK HERE |
Following the live call, a replay will be
available on the Company's website, www.intelgenx.com, under Investor
Relations".
About IntelGenx:
IntelGenx is a drug delivery company focused on the development
of oral controlled-release products as well as novel rapidly disintegrating
delivery systems. IntelGenx uses its unique multiple layer delivery system to
provide zero-order release of active drugs in the gastrointestinal tract.
IntelGenx has also developed novel delivery technologies for the rapid delivery
of pharmaceutically active substances in the oral cavity based on its experience
with rapidly disintegrating films. IntelGenx' development pipeline includes
products for the treatment of indications such as severe depression,
hypertension, erectile dysfunction, migraine, insomnia, CNS indications,
idiopathic pulmonary fibrosis, oncology and pain, as well as animal health
products. More information is available about the company at www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about
IntelGenx' operating results and business prospects that involve substantial
risks and uncertainties. Statements that are not purely historical are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933,
as amended.
These statements include, but are not limited to, statements
about IntelGenx' plans, objectives, expectations, strategies, intentions or
other characterizations of future events or circumstances and are generally
identified by the words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar expressions. All
forward looking statements are expressly qualified in their entirety by this
cautionary statement. Because these forward-looking statements are subject to a
number of risks and uncertainties, IntelGenx' actual results could differ
materially from those expressed or implied by these forward looking statements.
Factors that could cause or contribute to such differences include, but are not
limited to, those discussed under the heading "Risk Factors" in IntelGenx'
annual report on Form 10-K for the fiscal year ended December 31, 2013, filed
with the United States Securities and Exchange Commission and available at
www.sec.gov, and also filed with Canadian
securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to
update any such forward-looking statements.
Each of the TSX Venture Exchange and OTCQX has neither
approved nor disapproved the contents of this press release.
CONTACT:
Paul A. Simmons
Chief Financial Officer
IntelGenx
Technologies Corp.
T: +1 514-331-7440
F: +1 514-331-0436
www.intelgenx.com
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Apr 2023 to Apr 2024